At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 240 enrolled
Drug / intervention
Fampridine-SR +1 moredrug
Likely dose
Fampridine-SR 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR (10 mg b.i.d. [Bis in Die, Twice Daily]) in Patients With Multiple Sclerosis
In Brief
A Phase 3 clinical trial evaluating Fampridine-SR and Placebo for Multiple Sclerosis. Completed, enrolled 240 participants across 40 sites in 2 countries.
Detailed Summary
The purpose of the study is to show that individuals treated with Fampridine-SR tablets are significantly more likely to have consistent improvements in their walking than those treated with placebo tablets.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis
CountriesCanada, United States
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2007
First PostedJun 2007
Primary CompletionFeb 2008
Study CompletionMay 2008
TodayJul 2026
First PostedJun 7, 2007
Enrollment StartMay 1, 2007
Primary CompletionFeb 1, 2008
Study CompletionMay 1, 2008
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 19.1 years ago
Interventions
Fampridine-SRdrug
Tablets, 10 mg, twice daily, 9 weeks
Placebodrug
placebo (sugar pill)